A combined inhibitor of matrix metalloproteinase activity and tumour necrosis factor-α processing attenuates experimental autoimmune neuritis

Brain

Volumn 120, Issue 10, 1997, Pages 1895-1905

  Redford, E J ^a   Smith, K J ^a   Gregson, N A ^a   Davies, M ^a   Hughes, P ^b,c   Gearing, A J H ^c   Miller, K ^c   Hughes, R A C ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c British Biotech Pharmaceuticals Ltd   (United Kingdom)

Author keywords

Demyelination; Experimental autoimmune neuritis; Inflammation; Matrix metalloproteinases; Tumour necrosis factor

Indexed keywords

BB 1101; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DEMYELINATING DISEASE; DISEASE SEVERITY; ETIOLOGY; FEMALE; GUILLAIN BARRE SYNDROME; MALE; NEURITIS; NONHUMAN; PATHOGENESIS; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; RAT; SYMPTOM;

ANIMALS; DEXAMETHASONE; DRUG COMBINATIONS; EXTRACELLULAR MATRIX; FEMALE; GELATINASES; IMMUNOHISTOCHEMISTRY; MALE; METALLOENDOPEPTIDASES; NEURITIS, AUTOIMMUNE, EXPERIMENTAL; PENTOXIFYLLINE; PROTEASE INHIBITORS; RATS; RATS, INBRED LEW; SCIATIC NERVE; TISSUE DISTRIBUTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030860443     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/120.10.1895     Document Type: Article

References (52)

1. Asbury AK, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. Medicine 1969; 48: 173-215.
2. Beckett RP, Davidson AH, Drummond AH, Huxley P, Whittaker M. Recent advances in matrix metalloproteinase inhibitor research. Drug Discov Today 1996; 1: 16-26.
3. Beutler B. Cerami A. Cachectin, cachexia, and shock. [Review]. Annu Rev Med 1988; 39: 75-83.
4. Challacombe SJ, Czerkinsky C, Rees A. Solid-phase radio-immunoassay of class specific antibodies to whole bacteria and soluble antigens. In: Kemeny DM, and Lessof MH, editors. Recent developments in RAST and other solid-phase immunoassay systems. Amsterdam: Excerpta Medica, 1983; 54-64.
5. Chandler S, Coates R, Gearing A, Lury J, Wells G, Bone E. Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett 1995; 201: 223-6.
6. Chantry A, Gregson NA, Glynn P. A novel metalloproteinase associated with brain myelin membranes. Isolation and characterization. J Biol Chem 1989; 264: 21603-7.
7. Corkill DJ, Woolley K, Guard S, Wright A, Galloway WA, Thomas SW, et al. The effect of a novel inhibitor of tumour necrosis factor α (TNFα) processing, BB-1101, in experimental autoimmune encephalomyelitis. Br J Pharmacol 1995; 116: 8P.
8. Demaria S. Schwab R, Gottesman SR, Bushkin Y. Soluble beta 2-microglobulin-free class 1 heavy chains are released from the surface of activated and leukemia cells by a metalloprotease. J Biol Chem 1994; 269: 6689-94.
9. DiStefano PS, Chelsea DM, Schick CM, McKelvy JF. Involvement of a metalloprotease in low-affinity nerve growth factor receptor truncation: inhibition of truncation in vitro and in vivo. J Neurosci 1993; 13: 2405-14.
10. Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, et al. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 1994; 370: 555-7.
11. Gearing AJH, Beckett P, Christodoulou M, Churchill M, Clements JM, Crimmin M, et al. Matrix metalloproteinases and processing of pro-TNFα. [Review]. J Leukocyte Biol 1995; 57: 774-7.
12. Gijbels K, Steinman L. Gelatinase B producing cells in multiple sclerosis lesions [abstract] J Cell Biochem 1994; Suppl 18D: 143.
13. Gijbels K, Masure S, Carton H, Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 1992; 41: 29-34.
14. Gijbels K, Proost P, Masure S, Carton H, Billiau A, Opdenakker G. Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. J Neurosci Res 1993; 36: 432-40.
15. Gijbels K, Galardy RE, Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest 1994; 94: 2177-82.
16. Griffin JW, Li CY, Ho TW, Xue P, Macko C, Gao CY, et al. Guillain-Barré syndrome in northern China. The spectrum of neuropathological changes in clinically defined cases. [Review]. Brain 1995; 118: 577-95.
17. Hartung HP, Schafer B, Heininger K, Stoll G, Toyka KV. The role of macrophages and eicosanoids in the pathogenesis of experimental allergic neuritis. Serial clinical, electrophysiological, biochemical and morphological observations. Brain 1988; 111: 1039-59.
18. Hartung HP, Jung S, Stoll G, Zielasek J, Schmidt B, Archelos JJ, Toyka KV. Inflammatory mediators in demyelinating disorders of the CNS and PNS. [Review]. J Neuroimmunol 1992; 40: 197-210.
19. Hartung HP, Pollard JD, Harvey GK, Toyka KV. Immunopathogenesis and treatment of the Guillain-Barré syndrome. [Review]. Muscle Nerve 1995; 18: 137-53.
20. Harvey GK, Pollard JD. Patterns of conduction impairment in experimental allergic neuritis. An electrophysiological and histological study. J Neurol Neurosurg Psychiatry 1992a; 55: 909-15.
21. Harvey GK, Pollard JD. Peripheral nervous system demyelination from systemic transfer of experimental allergic neuritis serum. J Neuroimmunol 1992b; 41:159-66.
22. Harvey GK, Gold R, Hartung HP, Toyka KV. Non-neural-specific T lymphocytes can orchestrate inflammatory peripheral neuropathy. Brain 1995; 118: 1263-72.
23. Hewson AK, Smith T, Leonard JP, Cuzner ML. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflamm Res 1995; 44: 345-9.
24. Hibbs MS, Hoidal JR, Kang AH. Expression of a metalloproteinase that degrades native type V collagen and denatured collagens by cultured human alveolar macrophages. J Clin Invest 1987; 80: 1644-50.
25. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem.1981; 29: 577-80.
26. Hughes RAC Guillain-Barré syndrome. London: Springer-Verlag, 1990.
27. Italian Guillain-Barré Study Group. The prognosis and main prognostic indicators of Guillain-Barré syndrome: a multicentre prospective study of 297 patients. Brain 1996; 119: 2053-61.
28. Kadlubowski M, Hughes RAC, Gregson NA. Experimental allergic neuritis in the Lewis rat: characterization of the activity of peripheral myelin and its major basic protein P2. Brain Res 1980; 184: 439-54.
29. Leca G, Mansur SE, Bensussan A. Expression of VCAM-1 (CD106) by a subset of TCR gamma delta-bearing lymphocyte clones. Involvement of a metalloprotease in the specific hydrolytic release of the soluble isoform. J Immunol 1995; 154: 1069-77.
30. Maeda A, Sobel RA. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 1996; 55: 300-9.
31. Maeda Y, Maeda R, Prineas JW, Ledeen RW. Phosphatidylserine suppresses myelin-induced experimental allergic neuritis (EAN) in Lewis rats. J Neuropathol Exp Neurol 1994; 53: 672-7.
32. Mariani SM, Matiba B, Baumler C, Krammer PH. Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur J Immunol 1995; 25: 2303-7.
33. McGeehan GM, Becherer JD, Bast RC Jr, Boyer CM, Champion B, Connolly KM, et al. Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature 1994; 370: 558-61.
34. Mohler KM, Sleath PR, Fitzner JN, Cerretti DP, Alderson M, Kerwar SS, et al. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 1994; 370: 218-20.
35. Montgomery AM, Sabzevari H, Reisfeld RA. Production and regulation of gelatinase B by human T-cells. Biochim Biophys Acta 1993; 1176: 265-8.
36. Mullberg J, Durie FH, Otten-Evans C, Alderson MR, Rose-John S, Cosman D, et al. A metalloprotease inhibitor blocks the shedding the IL-6 receptor and the p60 TNF receptor. J Immunol 1995; 155: 5198-205.
37. Murphy G, Atkinson S, Ward R, Gavrilovic J, Reynolds JJ. The role of plasminogen activators in the regulation of connective tissue metalloproteinases. [Review]. Ann NY Acad Sci 1992; 667: 1-12.
38. Nakayasu H, Ota K, Tanaka H, Irie H, Takahashi K. Suppression of actively induced and passively transferred experimental allergic neuritis by cyclosporin A [see comments]. J Neuroimmunol 1990; 26: 219-27. Comment in: J Neuroimmunol 1991; 31: 89-90.
39. Nakayasu H, Ota K, Tanaka H, Irie H, Takahashi K. Suppression of actively induced and passively transferred experimental allergic neuritis by cyclosporin A [see comments]. J Neuroimmunol 1990; 26: 219-27. Comment in: J Neuroimmunol 1991; 31: 89-90.
40. Raine CS. Multiple sclerosis: TNF revisited, with promise [comment]. [Review]. Nat Med 1995; 1: 211-4. Comment on: Nat Med 1995; 1: 244-8.
41. Raine CS. Multiple sclerosis: TNF revisited, with promise [comment]. [Review]. Nat Med 1995; 1: 211-4. Comment on: Nat Med 1995; 1: 244-8.
42. Redford EJ, Hall SM, Smith KJ. Vascular changes and demyelination induced by the intraneural injection of tumour necrosis factor. Brain 1995; 118: 869-78.
43. Romanic AM, Madri JA. The induction of 72-kD gelatinase in T cells upon adhesion to endothelial cells is VCAM-1 dependent. J Cell Biol 1994; 125: 1165-78.
44. Rosenberg GA. Matrix metalloproteinases in brain injury. [Review]. J Neurotrauma 1995; 12: 833-42.
45. Rosenberg GA, Kornfeld M, Estrada E, Kelley RO, Liotta LA, Stetler-Stevenson WG. TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res 1992; 576: 203-7.
46. Rosenberg GA, Dencoff JE, McGuire PG, Liotta LA, Stetler-Stevenson WG. Injury induced 92-kilodalton gelatinase and urokinase expression in rat brain. Lab Invest 1994; 71 417-22.
47. Spies JM, Westland KW, Bonner JG, Pollard JD. Intraneural activated T cells cause focal breakdown of the blood-nerve barrier. Brain 1995; 118: 857-68.
48. Stoll G, Jung S, Jander S, van der Meide P, Hartung HP. Tumor necrosis factor-alpha in immune-mediated demyelination and Wallerian degeneration of the rat peripheral nervous system. J Neuroimmunol 1993; 45: 175-82.
49. Waksman BH, Adams RD. Allergic neuritis: an experimental disease of rabbits induced by the injection of peripheral nervous tissue and adjuvants. J Exp Med 1956; 102: 213-25.
50. Watts PM, Taylor WA, Hughes RA. High-dose methylprednisolone suppresses experimental allergic neuritis in the Lewis rat. Exp Neurol 1989; 103: 101-4.
51. Weiss SJ, Peppin G, Ortiz X, Ragsdale C, Test ST. Oxidative autoactivation of latent collagenase by human neutrophils. Science 1985; 227: 747-9.
52. Woessner JF. Introduction to serial reviews: the extracellular matrix. FASEB J 1993: 7: 735-6.